Theoretical innovation guides the research and development

In recent years, the development of traditional Chinese medicine has received widespread attention at the national level. , Promote the high -quality development and move towards the world. As a Chinese traditional Chinese medicine TOP10 company, the establishment of Ling Pharmaceutical has always adhered to the development strategy of "market leader, technology -driven" in 30 years, firmly grasped the main tone of scientific and technological innovation, and promoted the development of new drugs with theoretical innovation. Innovative patent Chinese medicine has solved difficulties for multiple diseases.

The disease is widely existed in a variety of internal injuries that are suspicious of diseases and diseases. Both medical masterpieces and medical masters of all ages mentioned the veins and the doctrine of linked diseases, but there were no systematic in -depth research, nor did they not form a complete theoretical system. After continuous exploration and innovation of Ling Pharmaceutical, the system has established a theoretical system of neat disease, becoming the company's unique core competitiveness of science and technology. "Listing theory and its application research" won the second prize of national scientific and technological progress in 2006. This research has improved the level of prevention and treatment of difficult diseases and driving the research and development of innovative drugs.

There are more than 330 million cardiovascular patients in my country, and about 2 of each death died of cardiovascular disease and at least one person died of cerebrovascular disease. These major diseases bring a heavy burden on patients and families and society. Lingling Pharmaceuticals, under the guidance of the above diseases, layout, developed Tongxinluo capsules, ginseng pine -hearted capsules, Qiqian Qiangxin, and Qiqiang Qiangxin under the guidance of the theory of linked disease theory. Innovative patent varieties such as capsules have become the leading products in the market of cardiovascular and cerebrovascular diseases and diabetes in my country.

Tongxinluo Capsules, Ginseng Yangxin Capsules, and Qiqiang Qiangxin Capsules are all national key new products, national medical insurance categories, and national basic drug directory varieties. Chronic heart failure and other diseases have benefited tens of millions of patients.

Tongxin Capsules, as a new patented medicine for microvascular lesions caused by coronary heart disease, cerebral infarction, and diabetes, is the only basic medication for the treatment of cardiovascular and cerebrovascular diseases that has won three national science and technology awards. Among them, the original research of the group won the second prize of the National Science and Technology Progress of 2000, which opened up a new way to treat the treatment different from the treatment of coronary heart disease; theoretical research won the second prize of national science and technology progress in 2006; The worm drug super crushing technology won the second prize of the 2007 National Technology Invention. This technology innovates the production process, making it easier to absorb patients after taking it.

Ginseng Yangxin Capsule is a Chinese patent medicine that has won the second prize of national scientific and technological progress. It is confirmed by experiments that the therapeutic disorders with a multi -ion channel and non -ion channel integration and regulation are confirmed. Premature beats, paroxysmal atrial fibrillation and chronic arrhythmia. Ginseng Yangxin Capsule provides new therapeutic drugs for the treatment of premature premature combination with the treatment room, and at the same time fills the gap of chronic arrhythmia treatment drugs.

Qiqiang Qiangxin Capsule is the first application of the theory of applying collateral disease to explore the laws and treatment of chronic heart failure, and guide new patent drugs to develop research and development. Heart failure is the ultimate lesion of death caused by various heart diseases. In recent decades, major breakthrough progress has been rare. Studying effective drugs for the treatment of heart failure is still a major issue in the international medical community. A number of evidence -based medical research has widely used the Qiqian Qiangxin capsules with the four new types of new drugs. As a result, it is confirmed that the Qiqian Qiangxin capsule not only has the comprehensive effect of first and second -line western medicine, but also has to reduce the apoptosis of myocardial cells and improve energy metabolism. The role shows the unique advantage of the medicine. The results of the study of chronic heart failure and evidence based on the treatment of Chronic Capsule Capsules were published in the top international cycle magazine "American Heart Society Magazine" (JACC), and the editorial department released a comment "Make the heart of the failure stronger -traditional Chinese medicine to us to us in Chinese medicine "Revelation" states that "this prospective research has opened a door to how to use the latest technology to study traditional traditional Chinese medicine activity in the synergy of the synergy of heart failure therapy", and the study has been included in the academic highlights of the year.

After the listing of Tongxinluo, Gongsong Yangxin, and Qiqiang Qiangxin Capsule, the "TCM Poems Construction and the Prevention of Microvascular Disease Prevention" project, which mainly studies the listing of the listing of Chinese medicine, won the first prize of national science and technology progress in 2019. This is my country Medical and Health. The only national scientific and technological progress first prize in the year. The award obtained not only proved the clinical efficacy of three products in cardiovascular and cerebrovascular diseases, but also explained the charm of combining Chinese medicine and modern technology.

The projects that have won this time have conducted research and made breakthroughs from the three aspects of theory, mechanism, and clinical clinical. There are three major innovation points. First, the system has established the theory of guiding the prevention and control of microvascular lesions, which belongs to the major theoretical original results of academic research in traditional Chinese medicine; the second is that the study clarifies the commonality of cardiovascular and cerebrovascular diseases and diabetic nephropathy that seriously endangers human health. The mechanism is microvascular lesions, and the protection of microvascular endothelial cells is the core mechanism for treating microvascular lesions. The National 973 Planning Project Acceptance Expert Group agrees that the project has "a major breakthrough in the treatment of microvascular lesions in Chinese medicine"; third, the project uses internationally recognized by the project internationally Evidence -based medical research methods have carried out a large number of clinical trials to solve major problems in the international medical community -Tongxinluo Capsule solves the problem of acute myocardial infarction without reinstatement. New drugs have filled the drug treatment of sinus heartbeat overlap, premature battle, fasting and slow treatment, and integrated tuning. The National 973 Planning Project Acceptance Expert Group claims that this study "created 'theory+clinical+new medicine+experiment+evidence -based" integrated Chinese medicine academic innovation and transformation model, the combination of traditional Chinese medicine theoretical innovation and modern science and technology, produced majority Original results have been demonstrated for the inheritance and innovation development of traditional Chinese medicine. "